388 related articles for article (PubMed ID: 30942107)
1. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
Tran TAN
Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
[TBL] [Abstract][Full Text] [Related]
2. Undifferentiated Sarcoma as Intermediate Step in the Progression of Malignant Melanoma to Rhabdomyosarcoma: Histologic, Immunohistochemical, and Molecular Studies of a New Case of Malignant Melanoma With Rhabdomyosarcomatous Differentiation.
Tran TAN; Linos K; de Abreu FB; Carlson JA
Am J Dermatopathol; 2019 Mar; 41(3):221-229. PubMed ID: 30085960
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
[TBL] [Abstract][Full Text] [Related]
4. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
[TBL] [Abstract][Full Text] [Related]
5. The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report.
Røe OD; Wahl SG
J Med Case Rep; 2017 Mar; 11(1):82. PubMed ID: 28343447
[TBL] [Abstract][Full Text] [Related]
6. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
[TBL] [Abstract][Full Text] [Related]
7. Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Indini A; Tondini CA; Mandalà M
Future Oncol; 2019 Mar; 15(9):967-977. PubMed ID: 30638071
[TBL] [Abstract][Full Text] [Related]
8. Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.
Popescu A; Haidar A; Anghel RM
Rom J Intern Med; 2018 Jun; 56(2):122-126. PubMed ID: 29168975
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation-positive folliculotropic metastatic melanoma.
Brick KE; Halling KC; Khan YK; Peters MS
Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
[TBL] [Abstract][Full Text] [Related]
11. [Malignant melanoma treated with radical chemotherapy, resemblance histology of melanoma to soft tissue sarcomas, case report].
Bílek O; Tuček S; Veselý K; Fabian P; Robešová B; Adámková Krákorová D; Lakomý R; Svoboda M; Jurečková A; Halámková J; Králová J; Sikulíncová L; Podhorec J; Tomášek J; Kiss I; Vyzula R
Klin Onkol; 2013; 26(1):42-6. PubMed ID: 23528172
[TBL] [Abstract][Full Text] [Related]
12. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
13. Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor.
Bardarov S; Michael CW; Lucas D; Pang Y; Pu RT
Diagn Cytopathol; 2008 Oct; 36(10):754-7. PubMed ID: 18773432
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
17. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
19. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
20. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]